GSK plc received a positive opinion from the European CHMP on September 24, 2024, for a fully liquid presentation of its Menveo vaccine, with marketing authorization expected by November 2024. Over 6 million doses of GSK's MenACWY vaccine have been distributed across Europe since 2017.